The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
yes they were set up has the head of the uk diagnostics consortium (government ******s) i went through all that with odx and abingdon. but looks like things are coming good finally and at a snip from when they floated over£1 gla ill certainly be holding for quite a while
Keeping it real of course but recognising quality when it's staring you in the face. This company has shown its metal through adversity .It had a much higher value before covid struck because it was always worth it. Those who know its story and want to wait a while, know they are onto a very, very good thing.
With you there Muck165. I'm sorry for tho
Just say it as I see it Invwell!
The really key things for me are diversification of business risk, growing number of developers, lack of CDMO/CRO competitors, growing need and demand for product, high automated manufacturing capability, prudent management, and solid and growing customer base.
Could things go wrong - of course! But I think that prospect is far far lower here than in many other AIM stocks.
Thank you Muck165. You certainly present a good case for investment here. I wish had invested when it was at 4p, when I had the chance, but no use crying over spilt milk. However, getting it around now would be a good time and so many products that are involved with. 2024 looks the year to be in here
Thank you as ever Muck165. Fingers crossed for Loop then and specifically sales of Septiloop. Still all looking so promising!
Loop also filed for a U.K. trademark to cover Septiloop on 30/10/23, which was granted on 19/1/24.
Getting their ducks in a row..
https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003973303
Further on this, I note that since Friday (when I last checked), Loop have updated the project time line on their website to confirm the following achievements;
1) Clinical trial results in Q4 23
2) Clinical trial publications in Q4 23 (I haven’t been able to find these yet).
3) Technical file submitted for CE marking in Q1 24
4 UKCA mark Q1 24
They are now also signposting first U.K. sales in Q2 24, ie in the next 3 months.
To be honest, I’m surprised they haven’t yet made an announcement about UKCA. Perhaps this recent site update signals they’re about to, maybe alongside some other announcement?
Anyone wanting to compare old to new, here is a snapshot of the timeline on 25 March (best I could get)
https://web.archive.org/web/20240325163648/https://loopdx.com/
and here it is now
https://loopdx.com/
Oh and lest we forget, new tax year starts 6/4 and with it all the new ISA allowances that will hit the market. Great time to be in this stock IMO.
April looks potentially good news heavy.
My bet is;
1) for a Loop/ABDX announcement re UKCA early next week.
2) an addition to the Boots own brand suite very soon - thyroid I’m guessing.
3) fair chance of Upfront UKCA and/or successful new funding round for them
And as a more off the wall prediction, I think we may see something more concrete about our relationship with Senzo, perhaps that the FOFH tests are based on its ALF platform, and I also have suspicions that something might be going on between ABDX and a company called Drummond Scientific in the States. Whether or not that turns out true, it is a simple fact that our involvement in US based entities, and reactions ABDX is getting from US based people, is increasing. Worth noting again that Yates said only in January that the US market is important and that 50% of our customers hail from there - that means 14/15 of our current projects are for US customers.
Absolutely amazing research Muck165. Fantastic that you've spotted an opportunity should there be another imminent spike due to news that Septiloop is registered in the UK and must therefore have UKCA, as you say. I will be ready for the next drop you characteristically see before good news these days, and will be adding again. This is all too good to miss IMO
Pleasure Apre. Next one I’m looking out for is Upfront MRHA registration, which they are strongly signposting as being imminent (note, this may well be registered under Pockit DX when it comes).
I don’t really know how these things work, but Loop have been waiting for UKCA for a while and would, I’d have thought, been setting up sales for when it arrived. If that’s the case, it might better explain Yates decision to waive fees for equity in FOFH. Would seem a lot less strange if he knew he had a nice Loop manufacturing order waiting in the wings.
One other thing - incorrect Sepsis antibiotic treatment isn’t helping the massive global AMR problem, so that’s another value add for Septiloop.
Muck, you are on a real roll at the moment . . . a mine of information. Thank you for sharing all the research and for the reasoned commentary.
You should be ABDX's PR man . . .
Final one from me, but just to note that after checking it’s clear that as part of the MRHA registration process a company MUST provide a copy of its conformity assessment. So there is no doubt that Septiloop, having now been registered, must have UKCA and can now be sold in the U.K.
Also worth remembering that the Health Ombudsman published a damning report on the state of U.K. Sepsis care in the Autumn, nicely titled “TIME TO ACT Severe Sepsis: Rapid diagnosis and treatment saves lives”, and in that report identified that NHS cost savings of £196m p/a could be achieved if that were to happen.
A great time to be launching this 3x more sensitive and 10x faster diagnostic into the U.K. market, and I think a great opportunity to get in or add here if you can before formal announcements are made.
https://www.ombudsman.org.uk/sites/default/files/Time_to_act_report.pdf
Really excited by this - to give a flavour of the market you need only look at this from the U.K. Sepsis Trust
“Every 3 seconds, someone in the world dies of sepsis. In the UK alone, 245,000 people are affected by sepsis with at least 48,000 people losing their lives in sepsis-related illnesses every year. This is more than breast, bowel and prostate cancer combined. Globally, sepsis claims 11 million lives a year. Yet, for many patients, with early diagnosis it is easily treatable.”
https://sepsistrust.org/about/
On 16/3/23 Salignostics/Salistick became registered with the MRHA, leading ABDX to say in a 31/3 RNS - “ We were pleased to see Salistick™ achieve Medicines and Healthcare products Regulatory Agency (MHRA) approval in March 2023 and will therefore be available for sale in the United Kingdom and we remain on target for an exclusive launch of Salistick™ on the Abingdon Simply Test™ website and on Amazon before the end of this financial year.”
I am excited to see, therefore that on 14/3/24 Loop Diagnostics/Septiloop achieved MRHA registration, which I am VERY reasonably assuming means that Septiloop, like Salistick, has now achieved UKCA and can be sold in the U.K. market.
Neither Loop or ABDX have said anything about this yet, but I’m sure it won’t be long and I would imagine it will give a very nice little shot in the arm of the SP! Remember, Septiloop is one of the products that ABDX has taken through tech transfer, scale up, and into manufacturing.
https://pard.mhra.gov.uk/manufacturer-details/110414 ((Salistick registration)
https://pard.mhra.gov.uk/manufacturer-details/117995 (Septiloop registration)
https://www.youtube.com/watch?v=4Z32joS9aD4 (See slide at 11 mins in)